What it is

CBL-514 is an injectable drug candidate from the Taiwanese company Caliway Biopharmaceuticals. It is being developed to reduce fat in a specific area, such as the abdomen, without surgery, and it has also been studied for cellulite.

How it works

Caliway describes CBL-514 as a first-in-class small molecule that selectively triggers apoptosis, a controlled form of cell death, in fat cells at the injection site.

What the research shows

Caliway reports that its phase 2b studies CBL-0204 and CBL-0205 met their primary endpoints for reducing abdominal fat.
A pooled analysis of 46 people from those studies, presented in 2026, reported that visceral fat measured by MRI fell with CBL-514 while it rose with placebo. The sample was small.
Two global phase 3 trials, SUPREME-01 and SUPREME-02, began in 2026, and the company expects results in 2027.
Most published results so far come from the company's own announcements.

Regulatory status

Investigational. Not approved anywhere. The FDA cleared the second phase 3 study to proceed in May 2026.

Storage and handling

Follow the supplier's label. Research materials should be kept sealed, cold and away from light.

Key references

Caliway Biopharmaceuticals. Announcements on the CBL-514 phase 2b and phase 3 programs, 2025 to 2026.
Phase 2 visceral fat analysis of CBL-0204 and CBL-0205, presented at the European Association for the Study of Diabetes meeting, 2026.
Search PubMed for CBL-514 studies

Educational content only

Peptide Knowledge is an educational reference. Nothing on this site is medical advice, a treatment recommendation or dosing guidance. Many compounds described here are not approved for human use and are sold for laboratory research only. Talk to a licensed clinician before starting, stopping or changing any medication or supplement.

CBL-514